Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.

CYP3A isoforms are responsible for the biotransformation of a wide variety of exogenous chemicals and endogenous steroids in human tissues. Two members of the CYP3A subfamily display developmentally regulated expression in the liver; CYP3A7 is expressed in the fetal liver, whereas CYP3A4 is the major cyrochrome P-450 isoform present in the adult liver. To gain insight into the descriptive ontogenesis of CYP3A isoforms during the neonatal period, we have developed several approaches to explore a neonatal liver bank. Although CYP3A4 and CYP3A7 are structurally closely related, they differ in their capacity to carry out monooxygenase reactions. We have cloned CYP3A4 and CYP3A7 and established stable transfectants in Ad293 cells to investigate their substrate specificities. The 16alpha hydroxylation of dehydroepiandrosterone is catalyzed by both proteins, but CYP3A7 has a higher affinity and maximal velocity than CYP3A4. Conversely, the conversion of testosterone into its 6beta derivative is essentially supported by CYP3A4. We used these two probes to determine the ontogenic evolution at the protein level; CYP3A7 was very active in the fetal liver and its activity was maximal during the first week following birth before to progressively decline and reached a very low level in adult livers. Conversely, the activity of CYP3A4 was extremely weak in the fetus and began to raise after birth to reach 30-40% of the adult activity after one month. CYP3A4 RNA accumulation displays a similar pattern of evolution; when probed with an oligonucleotide, its concentration increased rapidly after birth to reach a plateau as soon as the first week of age. These data supports the assumption that CYP3A4 expression is transcriptionally activated during the first week after birth and is accompanied by a simultaneous decrease of CYP3A7 expression, in such a way that the overall CYP3A protein content and the level of pentoxyresorufin dealkylase catalyzed by the two proteins remain nearly constant.

[1]  A. Rane,et al.  Human fetal and adult liver metabolism of ethylmorphine. Relation to immunodetected cytochrome P-450 PCN and interactions with important fetal corticosteroids. , 1989, Biochemical pharmacology.

[2]  J. Goldstein,et al.  Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. , 1993, Biochemical and biophysical research communications.

[3]  T. Cresteil,et al.  Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. , 1996, European journal of biochemistry.

[4]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[5]  H. Hamada,et al.  Molecular structure and evolutionary origin of human cardiac muscle actin gene. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Monsarrat,et al.  Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. , 1996, Cancer research.

[7]  J. Schuetz,et al.  Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. , 1989, Archives of biochemistry and biophysics.

[8]  M. Fromm,et al.  Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. , 2003, British journal of clinical pharmacology.

[9]  P. Beaune,et al.  Immunoquantification of epoxide hydrolase and cytochrome P-450 isozymes in fetal and adult human liver microsomes. , 1985, European journal of biochemistry.

[10]  F. Gonzalez,et al.  The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.

[11]  T. Kamataki,et al.  Purification and properties of cytochrome P-450 from homogenates of human fetal livers. , 1985, Archives of biochemistry and biophysics.

[12]  O. Mcbride,et al.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. , 1988, DNA.

[13]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.

[14]  R. Tukey,et al.  Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. , 1990, Cancer research.

[15]  P. Beaune,et al.  Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. , 1990, The Journal of pharmacology and experimental therapeutics.

[16]  L. Chung,et al.  Neonatal imprinting and hepatic cytochrome P-450. I. Comparison of testosterone hydroxylation in a reconstituted system between neonatally imprinted and nonimprinted rats. , 1980, Molecular pharmacology.

[17]  T. Cresteil,et al.  Effect of microsomal preparations and induction on cytochrome P-450-dependent monooxygenases in fetal and neonatal rat liver. , 1979, Biochemical pharmacology.

[18]  T. Kamataki,et al.  Immunochemical studies for the presence of P-450 HFLa, a form of cytochrome P-450 in human fetal livers in human hepatocellular carcinoma cells. , 1989, Journal of pharmacobio-dynamics.

[19]  T. Kamataki,et al.  Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450. , 1989, Journal of biochemistry.

[20]  D. Waxman,et al.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. , 1988, Archives of biochemistry and biophysics.

[21]  T. Aoyama,et al.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.

[22]  T. Kamataki,et al.  Isolation of a new human fetal liver cytochrome P450 cDNA clone: evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers. , 1989, Archives of biochemistry and biophysics.

[23]  O. Pelkonen,et al.  The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  C. Funck-Brentano,et al.  CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. , 1993, Pharmacogenetics.

[25]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[26]  A. Rane,et al.  Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. , 1991, British journal of clinical pharmacology.

[27]  P. Beaune,et al.  Cytochrome P-450 monooxygenase activities in human and rat liver microsomes. , 1981, European journal of biochemistry.

[28]  M. Buendia,et al.  Transcription of woodchuck hepatitis virus in the chronically infected liver. , 1985, The EMBO journal.

[29]  S. Tagawa,et al.  Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. , 1993, European journal of biochemistry.

[30]  T. Cresteil,et al.  Expression of CYP2D6 in developing human liver. , 1991, European journal of biochemistry.

[31]  B. Monsarrat,et al.  Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. , 1994, Cancer research.

[32]  L. Swenson,et al.  Developmental expression of human microsomal epoxide hydrolase. , 1994, The Journal of pharmacology and experimental therapeutics.

[33]  P. Beaune,et al.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. , 1983, Biochemistry.

[34]  J. Hakkola,et al.  Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. , 1994, Biochemical pharmacology.

[35]  S. Tagawa,et al.  Genomic organization of human fetal specific P-450IIIA7 (cytochrome P-450HFLa)-related gene(s) and interaction of transcriptional regulatory factor with its DNA element in the 5' flanking region. , 1992, Biochimica et biophysica acta.

[36]  L. Marnett,et al.  Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. , 1989, Cancer research.

[37]  K. Arai,et al.  Steroid 16α‐Hydroxylase from Human Fetal Liver; Inhibition by Steroids , 1980 .

[38]  T. Cresteil,et al.  Cytochrome P-450 expression in sudden infant death syndrome. , 1996, Biochemical pharmacology.

[39]  R. Mayer,et al.  Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. , 1985, Biochemical pharmacology.

[40]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[41]  J. Kolars,et al.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[42]  T. Kamataki,et al.  Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins. , 1995, Cancer research.

[43]  M. Vilarem,et al.  Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. , 1994, Biochemical and biophysical research communications.

[44]  P. Sharp,et al.  SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen. , 1981, Gene.

[45]  J. Schuetz,et al.  Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. , 1993, The Journal of clinical investigation.

[46]  F. Guengerich.  Characterization of human cytochrome P450 enzymes , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  H. Yamazaki,et al.  Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes. , 1995, Carcinogenesis.

[48]  C. Bonfils,et al.  The Fetal Specific GeneCYP3A7Is Inducible by Rifampicin in Adult Human Hepatocytes in Primary Culture , 1996 .

[49]  M. Soma,et al.  Fetus-specific expression of a form of cytochrome P-450 in human livers. , 1990, Biochemistry.

[50]  J. Goldstein,et al.  Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. , 1995, Biochemistry.

[51]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[52]  J. Schuetz,et al.  Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. , 1994, Pharmacogenetics.

[53]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.